Evidence map›Paper›PMID 36997583›Full record

ArticleScientific reports2023

Preclinical development of a first-in-class vaccine encoding HER2, Brachyury and CD40L for antibody enhanced tumor eradication.

Maria Hinterberger, Kathrin Endt, Barbara Bathke, Matthias Habjan, Alexander Heiseke, Marc Schweneker, Julia Von Rohrscheidt, Cigdem Atay, Paul Chaplin, Markus Kalla and 6 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 1 institution in 1 country.

Maria HinterbergerBavarian Nordic GmbH, Fraunhoferstr.13, 82152, Planegg, Germany. mahi@bavarian-nordic.com.
Kathrin EndtBavarian Nordic GmbH, Fraunhoferstr.13, 82152, Planegg, Germany.
Barbara BathkeBavarian Nordic GmbH, Fraunhoferstr.13, 82152, Planegg, Germany.
Matthias HabjanBavarian Nordic GmbH, Fraunhoferstr.13, 82152, Planegg, Germany.
Alexander HeisekeBavarian Nordic GmbH, Fraunhoferstr.13, 82152, Planegg, Germany.
Marc SchwenekerBavarian Nordic GmbH, Fraunhoferstr.13, 82152, Planegg, Germany.
Julia Von RohrscheidtBavarian Nordic GmbH, Fraunhoferstr.13, 82152, Planegg, Germany.
Cigdem AtayBavarian Nordic GmbH, Fraunhoferstr.13, 82152, Planegg, Germany.
Paul ChaplinBavarian Nordic GmbH, Fraunhoferstr.13, 82152, Planegg, Germany.
Markus KallaBavarian Nordic GmbH, Fraunhoferstr.13, 82152, Planegg, Germany.
Jürgen HausmannBavarian Nordic GmbH, Fraunhoferstr.13, 82152, Planegg, Germany.
Carolin SchmittwolfBavarian Nordic GmbH, Fraunhoferstr.13, 82152, Planegg, Germany.
Henning LauterbachBavarian Nordic GmbH, Fraunhoferstr.13, 82152, Planegg, Germany.
Ariane VolkmannBavarian Nordic GmbH, Fraunhoferstr.13, 82152, Planegg, Germany.
Hubertus HochreinBavarian Nordic GmbH, Fraunhoferstr.13, 82152, Planegg, Germany.
José Medina-EcheverzBavarian Nordic GmbH, Fraunhoferstr.13, 82152, Planegg, Germany.
Bavarian Nordic (Germany) · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The induction of antiviral innate immunity by systemic immunization with live virus can be employed to positively impact the response to therapeutic vaccination. We previously demonstrated that systemic immunization with a non-replicating MVA encoding CD40 ligand (CD40L) enhances innate immune cell activation and function, and triggers potent antitumor CD8

Indexed as

Cancer VaccinesNeoplasmsAnimalsAntibodies, NeoplasmBrachyury ProteinCD40 LigandCD8-Positive T-LymphocytesHumansMiceVaccinia virusAntibodies, NeoplasmBrachyury ProteinCancer VaccinesCD40 Ligand

Identifiers

PMID36997583
PMCPMC10060934
OpenAlexW4361273472

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.